OBJECTIVE: To investigate the frequency of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in women with intrauterine fetal death, preeclampsia, preterm delivery, and small for gestational age (SGA) infants. METHODS: In a prospective cohort study, DNA from 2,000 pregnant women were analyzed for MTHFR C677T by DNA microarray (wild-type allele, C; mutant allele, T). RESULTS: One thousand six hundred seventy-five women completed the study. Of these, 16.6% (278 women with 556 genetic alleles) developed at least one pregnancy complication and were designated study cases. There were 1,397 women (with 2,794 genetic alleles) who served as controls. MTHFR C677T allele frequencies were significantly different between cases and controls (C [wild-type]: 346 of 556 [62%]; T [mutant]: 210 of 556 [38%] compared with C: 1,911 of 2,794 [68%]; T: 883 of 2,794 [32%]; P=.005; odds ratio [OR] 1.23, 95% confidence interval [CI] 1.06-1.42). Genotype distributions were also different between cases and controls (C/T+T/T [abnormal]: 174 of 278 [63%]; C/C [normal]: 104 of 278 [37%] compared with C/T+T/T: 728 of 1,397 [52%]; C/C 669 of 1,397 [48%]; P=.002; OR 1.54, 95% CI 1.18-2.02). The clinical effect of the MTHFR C677T polymorphism was restricted to women with SGA infants (P=.05; OR 1.33, 95% CI 1.00-1.77). No significant differences in genotype distributions were observed among women with intrauterine fetal death, preeclampsia, and preterm delivery. CONCLUSION: MTHFR C677T is a genetic marker for identifying women at increased risk of SGA infants. LEVEL OF EVIDENCE: II.
OBJECTIVE: To investigate the frequency of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in women with intrauterine fetal death, preeclampsia, preterm delivery, and small for gestational age (SGA) infants. METHODS: In a prospective cohort study, DNA from 2,000 pregnant women were analyzed for MTHFRC677T by DNA microarray (wild-type allele, C; mutant allele, T). RESULTS: One thousand six hundred seventy-five women completed the study. Of these, 16.6% (278 women with 556 genetic alleles) developed at least one pregnancy complication and were designated study cases. There were 1,397 women (with 2,794 genetic alleles) who served as controls. MTHFRC677T allele frequencies were significantly different between cases and controls (C [wild-type]: 346 of 556 [62%]; T [mutant]: 210 of 556 [38%] compared with C: 1,911 of 2,794 [68%]; T: 883 of 2,794 [32%]; P=.005; odds ratio [OR] 1.23, 95% confidence interval [CI] 1.06-1.42). Genotype distributions were also different between cases and controls (C/T+T/T [abnormal]: 174 of 278 [63%]; C/C [normal]: 104 of 278 [37%] compared with C/T+T/T: 728 of 1,397 [52%]; C/C 669 of 1,397 [48%]; P=.002; OR 1.54, 95% CI 1.18-2.02). The clinical effect of the MTHFRC677T polymorphism was restricted to women with SGA infants (P=.05; OR 1.33, 95% CI 1.00-1.77). No significant differences in genotype distributions were observed among women with intrauterine fetal death, preeclampsia, and preterm delivery. CONCLUSION:MTHFRC677T is a genetic marker for identifying women at increased risk of SGA infants. LEVEL OF EVIDENCE: II.
Authors: Roberto Romero; Digna R Velez Edwards; Juan Pedro Kusanovic; Sonia S Hassan; Shali Mazaki-Tovi; Edi Vaisbuch; Chong Jai Kim; Tinnakorn Chaiworapongsa; Brad D Pearce; Lara A Friel; Jacquelaine Bartlett; Madan Kumar Anant; Benjamin A Salisbury; Gerald F Vovis; Min Seob Lee; Ricardo Gomez; Ernesto Behnke; Enrique Oyarzun; Gerard Tromp; Scott M Williams; Ramkumar Menon Journal: Am J Obstet Gynecol Date: 2010-05 Impact factor: 8.661
Authors: Martin Kharrazi; Michelle Pearl; Juan Yang; Gerald N DeLorenze; Christopher J Bean; William M Callaghan; Althea Grant; Eve Lackritz; Roberto Romero; Glen A Satten; Hyagriv Simhan; Anthony R Torres; Jonna B Westover; Robert Yolken; Dhelia M Williamson Journal: Paediatr Perinat Epidemiol Date: 2012-01-31 Impact factor: 3.980
Authors: Laura Pickell; Qing Wu; Xiao-Ling Wang; Daniel Leclerc; Hana Friedman; Alan C Peterson; Rima Rozen Journal: Mamm Genome Date: 2011-07-19 Impact factor: 2.957
Authors: Julia Warner Gargano; Claudia B Holzman; Patricia K Senagore; M Lynne Reuss; Dorothy R Pathak; Karen H Friderici; Katherine Jernigan; Rachel Fisher Journal: Am J Obstet Gynecol Date: 2009-09 Impact factor: 8.661
Authors: Jerome F Strauss; Roberto Romero; Nardhy Gomez-Lopez; Hannah Haymond-Thornburg; Bhavi P Modi; Maria E Teves; Laurel N Pearson; Timothy P York; Harvey A Schenkein Journal: Am J Obstet Gynecol Date: 2017-12-14 Impact factor: 8.661
Authors: Hye Ah Lee; Eun Ae Park; Su Jin Cho; Hae Soon Kim; Young Ju Kim; Hwayoung Lee; Hye Sun Gwak; Ki Nam Kim; Namsoo Chang; Eun Hee Ha; Hyesook Park Journal: J Epidemiol Date: 2013-07-13 Impact factor: 3.211